Digestive calcitonin-secreting tumors of the foregut:: comparison with non-calcitonin-secreting tumors

被引:4
|
作者
Wuilmet, Laurent
Jovenin, Nicolas
Larbre, Helene
Levy-Bohbot, Nathalie
Diebold, Marie-Daniele
Jolly, Damien
Delemer, Brigitte
Thiefin, Gerard
Cadiot, Guillaume
机构
[1] Hop Robert Debre, Serv Hepatogastroenterol, Dept Gastroenterol, F-51092 Reims, France
[2] Hop Robert Debre, Dept Endocrinol, F-51092 Reims, France
[3] Hop Maison Blanche, Dept Stat & med Informat, Reims, France
[4] Inst Jean Godinoi, Biol Lab, F-51056 Reims, France
[5] Dept Pathol, Reims, France
关键词
calcitonin; endocrine tumors; foregut; liver metastases; pancreas; prognosis; tumoral differentiation;
D O I
10.1097/01.meg.0000230091.76168.f9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives Digestive calcitonin-secreting endocrine tumors are very rare lesions of the foregut. This study was undertaken to compare the characteristics and the prognosis of these tumors and those of non-calcitonin-secreting endocrine tumors. Methods All patients with a digestive endocrine tumor of the foregut followed up in Reims University Hospital and whose serum calcitonin levels were determined between 1988 and 2004 were included. Clinical and tumor characteristics of calcitonin-positive and calcitonin-negative patients were compared. Results Thirty-two patients were included. Among the five (15.6%) with high calcitonin levels (median: 340 pg/ml, range: 42-7460 pg/ml), only one tumor was functioning (diarrhea). Significant differences between patients with positive and negative calcitonin levels were, respectively: liver metastases [5 (100%) versus 11 (40.7%); P=0.04], type according to the World Health Organization 2000 histological classification [notably 4 (80%) versus 3 (12.5%) poorly differentiated endocrine carcinomas; P=0.02] and Ki67 proliferation index [median: 25% (range: 20-30%) versus 7% (0-80%); P=0.03]. The only calcitonin-positive well-differentiated endocrine carcinoma had a high proliferation index (30%). Survival also differed significantly (P=0.001), as all calcitonin-positive patients died, with a median survival of 22.6 months (range: 1.2-27.2 months), versus five (18.5%) calcitonin-negative patients. Median follow-up period for the latter was 42.3 months (range: 3.4-208 months). Conclusions The secretion of calcitonin appears predictive of a poor prognosis. Digestive endocrine calcitonin-secreting tumors correspond histopathologically to poorly differentiated or well-differentiated carcinomas with high proliferation indexes.
引用
收藏
页码:951 / 955
页数:5
相关论文
共 50 条
  • [41] ELECTROPHYSIOLOGICAL PROPERTIES OF CALCITONIN-SECRETING CELLS DERIVED FROM HUMAN MEDULLARY-THYROID CARCINOMA
    SAND, O
    JONSSON, L
    NIELSEN, M
    HOLM, R
    GAUTVIK, KM
    ACTA PHYSIOLOGICA SCANDINAVICA, 1986, 126 (02): : 173 - 179
  • [42] A CALCITONIN-SECRETING MEDULLARY THYROID CARCINOMA ASSOCIATED WITH MUCOSAL NEUROMAS, MARFANOID FEATURES, MYOPATHY AND PIGMENTATION
    CUNLIFFE, WJ
    FULTHORPE, JJ
    BLACK, MM
    HALL, R
    JOHNSTON, ID
    SHUSTER, S
    AMERICAN JOURNAL OF MEDICINE, 1970, 48 (01): : 120 - +
  • [43] Calcitonin-secreting neuroendocrine tumor of the larynx, a diagnostic challenge of a rare neoplasm: a case report and literature review
    Filippini, Daria Maria
    Abeshi, Andi
    Tober, Nastassja
    Marchese, Paola Valeria
    Andrini, Elisa
    Lamberti, Giuseppe
    Agosti, Roberto
    Molinari, Giulia
    Fermi, Matteo
    Presutti, Livio
    AME CASE REPORTS, 2024, 8
  • [44] Calcitonin-secreting pancreatic neuroendocrine tumor in a patient with elevated thyroid fine-needle aspirate calcitonin washout: A case report and review of the literature
    Mason, Darryl
    Leimbach, Robert
    Kitz, Robert
    Vietor, Robert
    Vietor, Nicole
    CLINICAL CASE REPORTS, 2022, 10 (01):
  • [45] CALCITONIN SECRETING PROPERTY OF IPRIFLAVONE IN THE PRESENCE OF ESTROGEN
    YAMAZAKI, I
    KINOSHITA, M
    LIFE SCIENCES, 1986, 38 (17) : 1535 - 1541
  • [46] PROLACTIN SECRETING TUMORS
    BESSER, GM
    THORNER, MO
    ACTA ENDOCRINOLOGICA, 1977, 85 : 17 - 17
  • [47] SECRETING TUMORS OF TESTIS
    STALPORT, J
    VANDENNOORTGATE, D
    BODDAERT, J
    ACTA CHIRURGICA BELGICA, 1977, 76 (02) : 167 - 176
  • [48] COMPARISON OF THE RESPONSES IN THE NOMIFENSINE TEST WITH HYPERPROLACTINEMIA DUE TO PROLACTIN-SECRETING PITUITARY-TUMORS AND NON-PROLACTIN-SECRETING HYPOTHALAMIC TUMORS
    KAMOI, K
    TCHUCHIDA, I
    SATO, H
    TANAKA, R
    ISHIGURO, T
    KANEKO, K
    IWASAKI, Y
    SHIBATA, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1981, 53 (06): : 1285 - 1287
  • [49] PLASMA CALCITONIN AND TUMORS
    TABOLLI, S
    VALTORTA, C
    SCARDA, A
    DERASMO, E
    MINISOLA, S
    ANTONELLI, R
    MEDORI, C
    MAZZUOLI, G
    TUMORI, 1983, 69 (03) : 227 - 230
  • [50] IMMUNOREACTIVE CALCITONIN IN NON-THYROID TUMORS
    HILLYARD, CJ
    COOMBES, RC
    GREENBERG, PB
    MACINTYRE, I
    CALCIFIED TISSUE RESEARCH, 1976, 21 : 304 - 309